Rad51 inhibitors may sensitize tumor cells to chemotherapeutic agents, render tumors to be more efficient in HRR, and to be more responsive to PARP inhibitors targeting HRR-deficient tumors with mutated BRCA1/2 genes. The gene discussed is RAD51; the disease is neoplasm.